| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 11.4 | 4.7 |
| Profit before tax | -38.5 | -21.5 |
| Net income | -38.5 | -21.5 |
| EPS (diluted, $ a share) | $-8.52 | $-5.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +141.9% |
|---|---|
| Operating margin | -265.3% |
10-Q filed with the SEC, NASDAQ: IAM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Iambic Therapeutics, Inc.: key numbers
- Share price
- $13.11Close, Nov 20
- Market cap
- $698M
- Shares outstanding
- 48.93MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Iambic Therapeutics, Inc.
All →Iambic Therapeutics Financial Results
Iambic Therapeutics reported third quarter 2026 financial results, highlighting a pro-forma cash position of $455 million following its IPO and upfront payments from AbbVie. The company reported year-to-date collaboration revenue of approximately $24 million and total operating expenses of $108 million. Key operational milestones included the launch of its Enchant v3 AI model and positive Phase 1/2 data for its HER2 inhibitor, IAM1363.
- Term
- Q3 2026
“Iambic’s mission is to make better technology for better medicines, and we believe that the past several months showed that at work across every part of our business. At ESMO, our updated clinical data showed the intracranial activity and tolerability for IAM1363, and we are preparing to start a registrational trial in 2027, subject to regulatory approval. We submitted the IND and have received a Safe-to-Proceed Letter for a Phase 1/2 trial for IAM217, our second wholly owned and platform-discovered candidate, with an anticipated IND submission for IAM-C1, our CDK2/4 inhibitor, close behind. We launched Enchant v3, a huge advance in the core AI technology that underpins our molecular superintelligence platform, and AbbVie and Bayer each chose to bring our platform to bear on their own discovery work through new Iambic partnerships. Our IPO gives us the resources to advance our pipeline through major inflection points and to keep scaling the platform behind it.”
Tom Miller, PhD, Co-Founder & CEO of Iambic
Iambic Therapeutics Director Evan Lockwood Rachlin Buys $11.5M of Stock
Evan Lockwood Rachlin, Director, bought 718,750 shares of Iambic Therapeutics, Inc. at $16.00 a share, worth $11.5M in total on Oct 16, 2026. Shares held after the trade: 2,588,248 (+38.4%).
- Value
- $11.5M
- Shares
- 718,750
- Price
- $16.00
- Role
- Director
- Holding change
- +38.4%
- Trade date
- Oct 16, 2026
Iambic Therapeutics Capital Raise
Iambic Therapeutics, Inc. filed an amended and restated certificate of incorporation and adopted restated bylaws in connection with the completion of its initial public offering (IPO). The filing formalizes the company's corporate governance structure as it transitions to a publicly traded entity on the Nasdaq Stock Market.